FDA Approves First mRNA Flu Vaccine; Moderna Shows 26.6% Efficacy Edge

The FDA has approved the first mRNA-based influenza vaccine, developed by Moderna, following a season with 32 million cases and 24,000 deaths in the US. The vaccine demonstrated 26.6% greater efficacy than conventional shots, marking a significant advancement in flu prevention. This approval could shift vaccination strategies and reduce seasonal burden, though long-term effectiveness and uptake remain uncertain.